ALG-072571 / Aligos Therap - LARVOL DELTA

A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice (EASL-ILC 2023) - "Liver targeted PD-L1 siRNA therapy may lead to restoration of immune responses against HBV and consequent clearance of HBV infection."

IO biomarker • Preclinical • Hepatitis B • Hepatology • Immune Modulation • Oncology • PD-1 • PD-L1 • PTPRC

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire) - "Aligos Therapeutics...announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023....'We look forward to sharing additional detail at the time of the conference and further results throughout the year'."

Clinical data • Preclinical • Gastrointestinal Cancer • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Oncology • Solid Tumor